Cerus Corporation (NASDAQ: CERS) and Uroplasty (NYSE:UPI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Profitability

This table compares Cerus Corporation and Uroplasty’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerus Corporation -164.39% -120.31% -65.38%
Uroplasty -31.58% -87.33% -60.82%

Institutional and Insider Ownership

62.6% of Cerus Corporation shares are held by institutional investors. 7.4% of Cerus Corporation shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cerus Corporation and Uroplasty’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cerus Corporation $36.83 million 7.05 -$61.75 million ($0.61) -3.90
Uroplasty N/A N/A N/A N/A N/A

Uroplasty has higher revenue, but lower earnings than Cerus Corporation.

Analyst Recommendations

This is a summary of current ratings and target prices for Cerus Corporation and Uroplasty, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerus Corporation 0 0 4 0 3.00
Uroplasty 0 0 0 0 N/A

Cerus Corporation presently has a consensus price target of $7.25, suggesting a potential upside of 204.62%. Given Cerus Corporation’s higher probable upside, equities research analysts plainly believe Cerus Corporation is more favorable than Uroplasty.

Summary

Cerus Corporation beats Uroplasty on 5 of the 8 factors compared between the two stocks.

Cerus Corporation Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Uroplasty Company Profile

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.